- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05422469
OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial (OBSESS)
Obsessive-compulsive disorder (OCD) has a lifetime prevalence of 2-3% and is a major cause of global disability.
Deep brain stimulation (DBS) is an effective treatment for patients with severe, treatment-resistant forms, but access to and utilization of this therapy remains minimal despite FDA approval via HDE. The investigator's goal is to determine the neurophysiological basis of key symptom domains underlying OCD and derive individual-specific stimulation parameters to improve consistency of outcomes and facilitate outpatient therapy delivery. To do so, the investigators take advantage of key novel DBS device features, including imaging-based "inverse solutions" to determine optimal stimulation parameters, as well as on-device neural recordings that will guide therapy delivery.
The investigators will recruit patients with OCD meeting established criteria for surgical evaluation. Each will be implanted with permanent DBS leads and temporary stereo-EEG (sEEG) electrodes. In the inpatient unit, the investigators will first demonstrate how these DBS leads anatomically engage these hub-like DBS target regions and physiologically affect pre-frontal networks. In the outpatient phase, the investigators implement the inverse solutions parameters in a double-blinded head-to-head trial to test whether these personalized parameter sets can reduce symptoms in the domain-specific manner in which the personalized parameters were designed. Doing so would be the first demonstration of data-derived, individual specific DBS programming. Demonstrating clinical outcomes comparable to those achieved by expert programmers but with software-generated stimulation parameters will help demystify the programming process and increase accessibility to this therapy. Finally, and critically, patients will provide chronic on-device recordings labeled with behavioral data from wearables and portables. These naturalistic data will transform the investigator's understanding of the physiological signatures of OCD and provide biomarkers of symptom severity, therapeutic response, and potentially side effects, which will guide future therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02912
- Brown University
-
Contact:
- Wael Asaad
- Email: wael_asaad@brown.edu
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Principal diagnosis of OCD, confirmed by Structured Clinical Interview for DSM-IV (SCID-IV), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 28;
- Men and women (non-pregnant) between ages 21 and 70;
- The patient has had at least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning;
- Comorbid signs and symptoms of depression deemed secondary (based on history and clinical judgment) to OCD with minimum score of 16 on the HAM-D;
- Has failed an adequate trial (≥3 months at the maximum tolerated therapeutic dose) of at least three of the following SSRIs: fluoxetine; fluvoxamine; citalopram; escitalopram; sertraline; paroxetine;
- Has failed an adequate trial (150 - 250 mg) of clomipramine;
- Has failed augmentation of one or more of the aforementioned drugs with at least one of the following antipsychotics: haloperidol; risperidone; quetiapine; zisprasidone; aripiprazole;
- Must have failed an adequate trial of CBT for OCD; defined as ≥20 sessions of documented exposure and response prevention (ERP) by an expert therapist;
- Stable psychotropic medical regimen for the month preceding surgery;
- Able to provide fully informed, written consent;
- A family member or significant other is available and willing to communicate with the research team if the patient's clinical status worsens (e.g., develops hypomania), and if necessary to accompany patients to study visits.
Exclusion Criteria:
- Has a lifetime diagnosis of psychotic disorder such as schizophrenia;
- Comorbid Tourette's Disorder is exclusionary if the tic symptoms are the same presenting problem or at equivalent severity/impairment with OCD symptoms;
- Alcohol or substance abuse/dependence within 6 months, excluding nicotine;
- Deemed at high risk of suicidal behavior or impulsivity;
- MMSE score < 24;
- Premorbid IQ estimate < 85;
- Any neurological or medical condition/disorder that makes the patient, in the opinion of the surgeon, a poor candidate to undergo the intended surgical procedures of the study;
- Pregnant or plans to become pregnant in the next 24 months;
- Need for diathermy;
- Anticipated need for periodic MRI scans;
- Any psychiatric disorder that, in the opinion of the Scientific Steering Group, may interfere with the candidate's ability to participate in study activities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medtronic Percept RC neurostimulator
|
Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Yale-Brown Obsessive-Compulsive Scale (YBOCS) Score
Time Frame: Through study completion, an average of 14 months
|
Severity of depression symptoms.
Changes in the Yale-Brown Obsessive Compulsive Scale survey/questionnaire. YBOCS is an assessment to rate symptoms of OCD on a scale of 0-50 (with a higher number indicating a more severe outcome ratings of OCD and 0 indicated no symptoms of OCD).
|
Through study completion, an average of 14 months
|
Change in Hamilton Depression Inventory (HAM-D) Score
Time Frame: Through study completion, an average of 14 months
|
Severity of depression symptoms.
Changes in the Hamilton Depression Inventory (HAM-D) score.
HAM-D is an assessment to rate symptoms of depression on a scale of 0-52 (with a higher number indicating a more severe outcome ratings of depression and 0 indicated no symptoms of depression).
|
Through study completion, an average of 14 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFA-NS-21-024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder (OCD)
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingObsessive Compulsive Disorder (OCD)United States
-
University of ArizonaActive, not recruitingObsessive-compulsive Disorder (OCD)United States
-
University of LeipzigGerman Research Foundation; Philipps University Marburg Medical CenterCompleted
-
New York State Psychiatric InstituteCompletedObsessive-Compulsive Disorder (OCD)United States
-
New York State Psychiatric InstituteCompletedObsessive Compulsive Disorder (OCD)United States
-
The University of Texas Health Science Center,...MedtronicRecruitingObsessive-Compulsive Disorder (OCD)United States
-
Haukeland University HospitalSorlandet Hospital HFActive, not recruitingObsessive Compulsive Disorder (OCD)
-
University of BathSouth London and Maudsley NHS Foundation Trust; Avon and Wiltshire Mental Health...UnknownObsessive Compulsive Disorder (OCD)United Kingdom
-
Assistance Publique - Hôpitaux de ParisRecruitingObsessive Compulsive Disorder OCDFrance
-
Universitätsklinikum Hamburg-EppendorfUnknownObsessive-compulsive Disorder (OCD)Germany
Clinical Trials on Medtronic Percept RC neurostimulator
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingTourette SyndromeUnited States
-
Chen LingPrince of Wales Hospital, Shatin, Hong Kong; Shenzhen Second People's HospitalCompletedParkinson DiseaseChina
-
University of California, San FranciscoNational Institutes of Health (NIH)RecruitingDystonic Cerebral Palsy | Dyskinetic Cerebral PalsyUnited States
-
Helen Mayberg, MDRecruitingMajor Depressive Disorder | Treatment Resistant DepressionUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
University Hospital, BonnMedtronicCompleted
-
University of PecsCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart FailureUnited States, Germany, South Africa, Canada, Czech Republic, Netherlands, Italy, Sweden
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingPain, Postoperative | Complex Regional Pain Syndromes | Spinal Cord Injuries | Nerve Injury | Post Herpetic Neuralgia | Post-Stroke Pain | Post Radiation Brain Injury | Post Radiation Plexopathy | Nerve Root AvulsionUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States